Literature DB >> 2563893

Effects of ingestion of glucose on GH and TSH secretion: evidence for stimulation of somatostatin release from the hypothalamus by acute hyperglycemia in normal man and its impairment in acromegalic patients.

T Shibasaki1, A Masuda, M Hotta, N Yamauchi, N Hizuka, K Takano, H Demura, K Shizume.   

Abstract

Ingestion of glucose is known to induce suppression of GH secretion in normal subjects and this phenomenon is often absent in acromegalic patients. To clarify the mechanism of GH suppression in acute hyperglycemia in normal subjects and disturbed GH response in acromegalic patients, the effects of acute hyperglycemia on plasma GH and TSH levels were examined in normal subjects and acromegalic patients. Plasma GH levels were significantly lowered 45-60 min after ingestion of 75 g glucose and elevated at 210 and 240 min in nine normal subjects. Plasma TSH levels were also significantly lowered between 45 and 120 min after ingestion; levels then gradually rose. Subcutaneous administration of 50 micrograms SMS 201-995, a long acting somatostatin analog, lowered plasma TSH levels in both normal subjects and acromegalic patients, and there was no significant difference in the degree of decrease in plasma TSH levels between the normal subjects and patients. These results, taken together with several reports that somatostatin suppresses TSH secretion as well as GH secretion, suggest that acute hyperglycemia stimulates somatostatin release from the hypothalamus, thus causing inhibition of GH and TSH secretion. However, in ten acromegalic patients, only two showed suppression of plasma GH levels to below 50% of basal level and the degree of suppression of TSH secretion was significantly less than in normal subjects in the glucose tolerance test. It is, therefore, suggested that somatostatin release in response to acute hyperglycemia is impaired in most acromegalic patients and that this abnormality may be one of causes for the absence of the normal GH response to acute hyperglycemia in this disorder.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2563893     DOI: 10.1016/0024-3205(89)90268-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome.

Authors:  G Tropeano; I Liberale; I P Vuolo; A Barini; G Caroli; P Carfagna; E Menini
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

2.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

3.  The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly.

Authors:  K Hanew; A Utsumi; A Sugawara; Y Shimizu; H Ikeda; K Abe
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

4.  On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes.

Authors:  David P Sonne; Asger Lund; Jens Faber; Jens J Holst; Tina Vilsbøll; Filip K Knop
Journal:  Endocr Connect       Date:  2014-10-02       Impact factor: 3.335

5.  Four features of temporal patterns characterize similarity among individuals and molecules by glucose ingestion in humans.

Authors:  Suguru Fujita; Yasuaki Karasawa; Masashi Fujii; Ken-Ichi Hironaka; Shinsuke Uda; Hiroyuki Kubota; Hiroshi Inoue; Yohei Sumitomo; Akiyoshi Hirayama; Tomoyoshi Soga; Shinya Kuroda
Journal:  NPJ Syst Biol Appl       Date:  2022-02-08

6.  Thyrotropin secretion during oral glucose tolerance test in acromegalic patients and control subjects.

Authors:  Erika Hubina; László Kovács; Zoltán Görömbey; István Szabolcs; Sándor Czirják; Miklós I Góth
Journal:  Endocrine       Date:  2003-11       Impact factor: 3.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.